oh dear
For the quarter ended March 31, 2024, AVITA Medical now expects commercial revenue to be in the range of US$11.0 million to US$11.3 million. This range is below the previously provided revenue guidance of US$14.8 million to US$15.6 million. The revision in guidance is attributable to a slower-than-expected conversion rate of new accounts for our expanded label of full-thickness skin defects.
Don't consider selling before profitability, page-246
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.75 |
Change
0.050(1.35%) |
Mkt cap ! $260.6M | |||
| Open | High | Low | Value | Volume |
| $3.74 | $3.88 | $3.72 | $970.4K | 256.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6788 | $3.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.84 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 20/12/2024 (20 minute delay) ? |
| AVH (ASX) Chart |
